{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:10:48Z","timestamp":1787505048987,"version":"build-2736575974"},"reference-count":45,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: In the context of modern cancer therapy, the management of adverse effects of systemic therapies can lead to the avoidance of underdosing and withdrawal and increases in the quality of the therapeutic act and the quality of life. This review offers an overview of the skin-related toxicities associated with Cabozantinib, a multikinase inhibitor (MKI) that is approved for treating advanced kidney cancer, hepatocellular carcinoma, and medullary thyroid cancer. It covers the most common dermatological side effects, such as palmar\u2013plantar erythrodysesthesia, stomatitis, hair alterations, xerosis, scrotal erythema, and subungual splinter hemorrhages. Additionally, this review includes suggested preventive strategies and management approaches based on the severity of these adverse effects.<\/jats:p>","DOI":"10.3390\/life15010072","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T09:54:27Z","timestamp":1736416467000},"page":"72","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cabozantinib Cutaneous Toxicity\u2014Comprehensive Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2840-1263","authenticated-orcid":false,"given":"Cristina Violeta","family":"Tutunaru","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"},{"name":"Department of Dermatology, Clinical Emergency County Hospital of Craiova, 200642 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-8048","authenticated-orcid":false,"given":"Dragos Ovidiu","family":"Alexandru","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanda Amelia","family":"Dracea","sequence":"additional","affiliation":[{"name":"Department of Biophysics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"},{"name":"Department of Radiotherapy, Clinical Emergency County Hospital of Craiova, 200642 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8535-9677","authenticated-orcid":false,"given":"Loredana","family":"Ungureanu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1702-7280","authenticated-orcid":false,"given":"Liliana Gabriela","family":"Popa","sequence":"additional","affiliation":[{"name":"Department of Oncologic Dermatology, \u201cElias\u201d Emergency University Hospital, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-576X","authenticated-orcid":false,"given":"Cristina","family":"Beiu","sequence":"additional","affiliation":[{"name":"Department of Oncologic Dermatology, \u201cElias\u201d Emergency University Hospital, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1158\/1535-7163.MCT-18-1399","article-title":"Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence","volume":"18","author":"Bergerot","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jamadermatol.2014.2734","article-title":"Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib","volume":"151","author":"Zuo","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102221","DOI":"10.1016\/j.ctrv.2021.102221","article-title":"Cabozantinib: An evolving therapy for hepatocellular carcinoma","volume":"98","author":"Hanna","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Santorsola, M., Capuozzo, M., Nasti, G., Sabbatino, F., Di Mauro, A., Di Mauro, G., Vanni, G., Maiolino, P., Correra, M., and Granata, V. (2024). Exploring the Spectrum of VEGF Inhibitors\u2019 Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice. Cancers, 16.","DOI":"10.3390\/cancers16020350"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.2017-0335","article-title":"Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma","volume":"23","author":"Schmidinger","year":"2018","journal-title":"Oncologist"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102333","DOI":"10.1016\/j.ctrv.2021.102333","article-title":"Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review","volume":"103","author":"McGregor","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_8","first-page":"48","article-title":"Cutaneous Toxicities of Molecular Targeted Therapies","volume":"12","author":"Stanculeanu","year":"2017","journal-title":"Maedica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma","volume":"77","author":"Rimassa","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Xue, Y., Feng, S., Li, G., and Zhang, C. (2023). Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: A pharmacovigilance disproportionality analysis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1160117"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdr580","article-title":"Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib","volume":"23","author":"Dranitsaris","year":"2012","journal-title":"Ann. Oncol.-Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_13","first-page":"73","article-title":"Cutaneous toxicities of targeted therapies in the treatment of hepatocellular carcinoma","volume":"6","author":"Silk","year":"2020","journal-title":"Hepatoma Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/ced.12694","article-title":"Incidence and risk of hand-foot skin reaction with Cabozantinib, a novel multikinase inhibitor: A meta-analysis","volume":"41","author":"Belum","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"METEOR investigators. Cabozantinib versus Everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus Sunitinib as Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2023-4-1","DOI":"10.7573\/dic.2023-4-1","article-title":"Real-world experience of Cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and\/or immune-checkpoint inhibitors","volume":"12","author":"Poon","year":"2023","journal-title":"Drugs Context"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000515551","article-title":"Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma","volume":"10","author":"Tovoli","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.2147\/OTT.S145295","article-title":"Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma","volume":"10","author":"Gerendash","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000327767","article-title":"Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment","volume":"4","author":"Farr","year":"2011","journal-title":"Case Rep. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12967-020-02612-5","article-title":"Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors","volume":"18","author":"Gulati","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1007\/s12011-023-03618-y","article-title":"A Potential Association of Zinc Deficiency and Tyrosine Kinase Inhibitor-Induced Hand-Foot Skin Reaction","volume":"201","author":"Yeh","year":"2023","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_23","unstructured":"National Institute of Cancer\u2014Cancer Therapy Evaluation Program (CTEP) (2024, June 17). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol."},{"key":"ref_27","unstructured":"U.S. Food and Drug Administration (2024, June 14). CABOMETYX\u2122 (Cabozantinib) Tablets, for Oral Use: Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208692s000lbl.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1634\/theoncologist.2008-0237","article-title":"Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs)","volume":"14","author":"Anderson","year":"2009","journal-title":"Oncologist"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.suponc.2010.12.007","article-title":"Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: Viewpoints from the medical oncologist, dermatologist, and oncology nurse","volume":"9","author":"Manchen","year":"2011","journal-title":"J. Support. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Xie, L., Xu, J., Guo, W., Wang, Z., Yao, Y., Li, J., Lin, J., Xiao, J., Yu, X., and Zhang, W. (2021). Management of Apatinib-Related Adverse Events in Patients with Advanced Osteosarcoma from Four Prospective Trials: Chinese Sarcoma Study Group Experience. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.696865"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Villa, A., and Kuten-Shorrer, M. (2023). Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098188"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3322\/caac.21704","article-title":"The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies","volume":"72","author":"Elad","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/jop.13064","article-title":"Is oral dysaesthesia a somatic symptom disorder?","volume":"49","author":"Kwong","year":"2020","journal-title":"J. Oral Pathol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Arena, C., Troiano, G., De Lillo, A., Testa, N.F., and Lo Muzio, L. (2018). Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients. BioMed Res. Int., 2018.","DOI":"10.1155\/2018\/5035217"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.oraloncology.2015.09.003","article-title":"Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors","volume":"51","author":"Yuan","year":"2015","journal-title":"Oral Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"omy105","DOI":"10.1093\/omcr\/omy105","article-title":"A rare cutaneous adverse effect secondary to cabozantinib therapy","volume":"2018","author":"Growcott","year":"2018","journal-title":"Oxf. Med. Case Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/EDBK_289911","article-title":"Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy","volume":"40","author":"Deutsch","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jaad.2017.06.044","article-title":"Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis","volume":"77","author":"Dai","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/bmt.2012.218","article-title":"Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant","volume":"48","author":"Parker","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4103\/ijd.ijd_818_22","article-title":"Tyrosine Kinase Inhibitors Induced Scrotal Ulcerations: Report of 2 Cases","volume":"68","author":"Samal","year":"2023","journal-title":"Indian J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-143-4-200508160-00021","article-title":"Subungual splinter hemorrhages: A clinical window to inhibition of vascular endothelial growth factor receptors?","volume":"143","author":"Robert","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e27077","DOI":"10.1002\/pbc.27077","article-title":"A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children\u2019s Oncology Group","volume":"65","author":"Chuk","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"82473","DOI":"10.18632\/oncotarget.12666","article-title":"Bevacizumab and wound-healing complications: A systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/ijd.15583","article-title":"Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine kinase inhibitor-related cutaneous adverse events with outcomes in metastatic renal cell carcinoma","volume":"60","author":"Lam","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clgc.2021.11.004","article-title":"Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients","volume":"20","author":"Martini","year":"2022","journal-title":"Clin. Genitourin. Cancer"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/1\/72\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:25:54Z","timestamp":1759919154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/1\/72"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["life15010072"],"URL":"https:\/\/doi.org\/10.3390\/life15010072","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]}}}